AI Summary
Theravance Biopharma will be acquired by Zymeworks for $17 per share, valuing TBPH at about $929 million, with shareholders receiving a CVR for 80% of future ampreloxetine net proceeds. The deal follows a comprehensive strategic review and monetization of the TRELEGY royalty, with closing anticipated in the second half of 2026, pending approvals. TBPH's strong YUPELRI franchise and ongoing ampreloxetine program anchor the value narrative.
Sentiment Rationale
Cash premium and CVR create immediate upside for TBPH shareholders; potential upside from CVR depends on future monetization, but closing risk persists.
Trading Thesis
TBPH could spike on deal news; primary upside hinges on closing and CVR monetization through 2026.
Market-Moving
- The $17 cash per share implies immediate TBPH upside versus recent trading.
- CVR captures 80% of future ampreloxetine proceeds for 10 years.
- Closing and shareholder approvals are near-term hurdles.
- TRELEGY royalty monetization history supports the deal rationale.
Key Facts
- Zymeworks to acquire Theravance Biopharma for $17 per share cash plus CVR.
- TBPH shareholders receive CVR for 80% of ampreloxetine net proceeds over 10 years.
- Premiums: 22% vs 3/3/2026 close; 10% vs VWAP since date.
- Close expected in 2H 2026, subject to shareholder approvals and closing conditions.
- TRELEGY royalty monetization for $225M in 2025 referenced as value context.
Companies Mentioned
- Theravance Biopharma, Inc. (TBPH): Definitive agreement to be acquired by Zymeworks; provides immediate cash and a CVR.
- Zymeworks Inc. (ZYME): Buyer; acquiring TBPH for $929M equity value; CVR structure adds future upside.
- Viatris, Inc. (VTRS): Collaborator on YUPELRI; deal context may influence TBPH asset value.
M&A
M&A-driven corporate development; TBPH's portfolio (YUPELRI) and potential ampreloxetine upside via CVR shape the value and risk balance in the deal.